PT  - JOURNAL ARTICLE
AU  - Zeng, Hesong
AU  - Zhang, Tianlu
AU  - He, Xingwei
AU  - Du, Yuxin
AU  - Tong, Yan
AU  - Wang, Xueli
AU  - Zhang, Weizhong
AU  - Shen, Yin
TI  - Impact of Hypertension on Progression and Prognosis in Patients with COVID-19 <em>A Retrospective Cohort Study in 1031 Hospitalized Cases in Wuhan, China</em>
AID  - 10.1101/2020.06.14.20125997
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.06.14.20125997
4099  - http://medrxiv.org/content/early/2020/07/24/2020.06.14.20125997.short
4100  - http://medrxiv.org/content/early/2020/07/24/2020.06.14.20125997.full
AB  - Objectives The main aim of our study is to observe clinical characteristics and effects of antihypertensive drugs in different hospitalized populations, and to further provide evidence to explore causes and specific clinical markers of the aggravation of COVID-19 in patients with underlying hypertension.Design This was a retrospective cohort study focusing on the clinical data of COVID-19 inpatients admitted at the early stage of pandemic.Setting A single center study conducted in Tongji Hospital, Tongji Medical College of Huazhong university of Science and Technology (Wuhan, China).Participants All 1031 inpatients diagnosed with COVID-19 according to Prevention and control Scheme for Novel Coronavirus Pneumonia published by National Health Commission of the People’s Republic of China and WHO interim guidance in Tongji hospital (Wuhan, China), from January 27, 2020, to March 8, 2020 with the cutoff date being March 30, 2020, were included in this study.Main outcome measures Demographic data, medical history, clinical symptoms and signs, laboratory findings, chest computed tomography (CT), treatment, and clinical outcomes were extracted from electronic medical records.Results 1031 COVID-19 inpatients were included in this study, of whom 866 were discharged and 165 were deceased in hospital. 73% of 165 deceased patients had chronic comorbidities. Patients with underlying diseases showed CFR 2.8 times as that of patients without. Senility and males were observed to be main risk factors for increased in-hospital case-fatality rate, with the odds ratio in multivariable regression being 2.94 (95%CI: 2.00 to 4.33; P <0.001) and 2.47 (95%CI: 1.65 to 3.70; P <0.001), respectively. The odds ratio of cases with composite endpoints for patients with simple hypertension was 1.53 (95%CI: 1.07 to 2.17; P=0.019). Senile patients with hypertension were proved to be at high risk early in the disease, which might be associated with the level of CRP, LDH, and eGFR. The odds ratio of case-fatality rate for patients with hypertension taking CCB group was 0.67 (95%CI: 0.37 to 1.20; P = 0.176). Among 271 severe cases without IKF, the odds ratio of case-fatality rate was 0.42 (95CI%: 0.18 to 0.99; P = 0.046) for patients in the CCB group after adjustment of age, sex, and underlying diseases.Conclusions Hypertension is not just a chronic underlying comorbidity, but also a risk factor affecting the severity of COVID-19 and does play a critical role in worsening patients’ clinical outcomes. Therefore, hypertension management in patients with COVID-19 should be regarded as a major challenge in the diagnostic and therapeutic strategies.Trial registration N.A.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe study was supported by COVID-19 Emergency Response Project of Wuhan Science and Technology Department (2020020201010018).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Institutional Review Board of Tongji Hospital, Wuhan, China, approved this retrospective study and written informed consent was waived (No. TJ-C20200140).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe raw data was extracted from electronic medical records with standardized data collection forms in Tongji Hospital (Wuhan, China), which had been approved by the Research Ethics Commission of Tongji Hospital, Tongji medical college of HUST. The data used to support the findings of this study are available from the corresponding author upon request.ACIAcute cardiac injuryALTAlanine aminotransferaseAPTTActivated partial thromboplastin timeASTAspartate aminotransferaseCCBCalcium channel blockersCCIRCase-critically ill rateCDCChinese Center for Disease Control and PreventionCFRCase-fatality rateCHDCoronary atherosclerotic heart diseaseCOPDChronic obstructive pulmonary diseaseCOVID-19Coronavirus disease 2019CRPC-reactive proteinCRRTContinuous renal replacement therapyDMDiabetes mellitusECMOExtracorporeal membrane oxygenationeGFRGlomerular filtration rateESRErythrocyte sedimentation rateIKFImpaired kidney functionIL-6Interleukin 6LDHLactate dehydrogenaseLOSLength of stayMAPMean arterial pressureNT-proBNPN-terminal pro-brain natriuretic peptideOOSOximeter oxygen saturationPTProthrombin timeRASRenin-angiotensin-aldosterone systemRASIRenin-angiotensin-aldosterone system inhibitorsSARS-CoV-2 IgGSARS-CoV-2 Immunoglobulin GSARS-CoV-2 IgMSARS-CoV-2 Immunoglobulin MScrSerum creatinineTNITroponin IWHOWorld Health Organization